Boehringer Mannheim's new clot buster.
D001709:Biotechnology; D004345:Drug Industry; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005818:Genetic Engineering; D006801:Humans; D016297:Mutagenesis, Site-Directed; D009203:Myocardial Infarction / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D017384:Sequence Deletion; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000627:therapeutic use*; D014481:United States
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator